Ascletis Pharma, Inc. (HK:1672) has released an update.
Ascletis Pharma Inc. has announced the initiation of two U.S. Phase I clinical trials for its innovative obesity treatment, ASC30, which is the first small molecule GLP-1 receptor agonist that can be administered both as a once-monthly injection and a once-daily oral tablet. With positive preclinical results showing significant weight loss and enhanced potency compared to existing medications, the company anticipates topline data from the trials in early 2025. ASC30’s dual administration methods offer a potentially attractive option for patients seeking flexibility in managing obesity.
For further insights into HK:1672 stock, check out TipRanks’ Stock Analysis page.
